Quick answers
- What is LYUMJEV KwikPen?
- LYUMJEV KwikPen is a brand name of Insulin lispro, a prescription medicine. The FDA NDC Directory lists 2 LYUMJEV KwikPen products in 2 strengths and forms.
- Who makes LYUMJEV KwikPen?
- Eli Lilly and Co holds the FDA application for LYUMJEV KwikPen (BLA761109, approved June 15, 2020).
- Is there a generic or store brand of LYUMJEV KwikPen?
- Yes. The FDA NDC Directory lists 23 other products with the same active ingredients, strength and form as a LYUMJEV KwikPen product. Ask your pharmacist whether one is right for you.
- What do pharmacies pay for LYUMJEV KwikPen?
- CMS lists a National Average Drug Acquisition Cost (NADAC) for 2 LYUMJEV KwikPen strengths and forms (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
- Has LYUMJEV KwikPen been recalled?
- No recall linked to LYUMJEV KwikPen products (by their NDC code or label) appears in the FDA enforcement reports we use.
What LYUMJEV KwikPen is
Each LYUMJEV KwikPen product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Insulin lispro · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| insulin lispro 100 units/mL injection, solution (subcutaneous) | LYUMJEV KwikPen | 22 products, 4 companies | DailyMed |
| insulin lispro 200 units/mL injection, solution (subcutaneous) | LYUMJEV KwikPen | 1 product, 1 company | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Insulin lispro →
FDA approval
- BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| BLA761109 | Eli Lilly and Co | June 15, 2020 | 2 |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| insulin lispro 100 units/mL injection, solution | Brand: LYUMJEV KwikPen | $10.15 per mL Generic of the same strength and form: $2.40–$10.19 per mL |
| insulin lispro 200 units/mL injection, solution | Brand: LYUMJEV KwikPen | $20.28 per mL |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list LYUMJEV KwikPen
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of LYUMJEV KwikPen products.
- Eli Lilly and Company2 products
Recalls
No recall linked to LYUMJEV KwikPen products (by their NDC code or label) appears in the FDA enforcement reports.
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.